Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Reports Q3 Revenue Jump

SAN DIEGO, Oct. 25 – Ciphergen Biosystems on Thursday posted third-quarter revenues of $5.4 million compared to $2.3 million for the same quarter a year ago, the company announced.

“This was a very strong quarter for Ciphergen, as our revenue growth accelerated and met plan,” William Rich, CEO of Ciphergen, said in a statement. “We believe that investment in our sales force and new product offerings are paying off, as well as the delivery of collaboration revenues through our Biomarker Centers.”

Ciphergen, based in Fremont, Calif., recorded a net loss of $6.9 million for the third quarter of 2001 compared to a loss of $6.2 for the year-ago quarter. Operating expenses rose to $11.2 million, with $3.3 million in R&D, for the third quarter of this year from $7.6 million, of which $2.0 million was R&D, in the same period in 2000.

As of September 30, 2001, Ciphergen had $81.6 million in cash, cash equivalents, and investments in securities.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.